Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Farxiga's generic name is dapagliflozin, an SGLT2 inhibitor used to treat type 2 diabetes, heart failure, and chronic kidney disease. Dosing, cost, and availability can differ between the brand and generic versions, and there are several other factors to consider before switching. See below to understand more about how dapagliflozin works, who should avoid it, and what side effects to watch for. If you are weighing this medication because of symptoms like excessive thirst, fatigue, swelling, or shortness of breath, it helps to clarify what may be driving them first. Take a free, instant, online symptom check to better understand your situation and get guidance on smart next steps.
Last reviewed for medical accuracy: 09/26/2026
What Is the Generic Name for Farxiga?
Farxiga is a prescription medication commonly used to manage type 2 diabetes and reduce the risk of heart and kidney complications in certain patients. Understanding its generic name, how it works, and what to expect can help you make informed decisions about your health.
Dapagliflozin helps your body remove excess sugar (glucose) by:
Because it works through the kidneys rather than by increasing insulin production, dapagliflozin can be used alone or in combination with other diabetes medications, including metformin or insulin.
Type 2 Diabetes Management
Heart Failure
Chronic Kidney Disease (CKD)
These benefits have been supported by large clinical trials and are reflected in guidelines from organizations such as the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD).
As with any medication, dapagliflozin can cause side effects. Most are mild, but you should be aware of:
If you experience severe symptoms—such as difficulty breathing, signs of a serious infection, or persistent stomach pain—seek medical help right away.
Dapagliflozin may interact with:
Always share your full medication list with your healthcare provider before starting dapagliflozin.
As prices and coverage vary, discuss options with your pharmacist or insurance provider.
Your doctor may recommend:
Promptly report unusual symptoms—such as dizziness, rapid heartbeat, or signs of infection—to your healthcare team.
If you experience any of the following, contact your doctor or emergency services:
For non-urgent concerns or to explore your symptoms from home, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker (https://ubiehealth.com/).
Knowing that Farxiga’s generic name is dapagliflozin can help you discuss options with your healthcare team, evaluate cost-saving opportunities, and better understand your treatment plan. While this guide covers key points, it’s not a substitute for personalized medical advice.
Speak to a doctor about any life-threatening or serious concerns, medication changes, or new symptoms. Your health is unique—professional guidance ensures the safest, most effective care for you.
(References)
* Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1108-1113. doi: 10.1016/j.numecd.2017.10.011. Epub 2017 Oct 18. PMID: 29174031.
* Donepudi S, Achanta S. Simultaneous Estimation of Saxagliptin and Dapagliflozin in Human Plasma by Validated High Performance Liquid Chromatography - Ultraviolet Method. Turk J Pharm Sci. 2019 Jun;16(2):227-233. doi: 10.4274/tjps.galenos.2018.46547. Epub 2019 Mar 27. PMID: 32454718; PMCID: PMC7227962.
* Vaduganathan M, Li D, Van Meijgaard J, Warraich HJ. Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States. J Card Fail. 2021 Nov;27(11):1280-1284. doi: 10.1016/j.cardfail.2021.06.013. Epub 2021 Jun 29. PMID: 34214650; PMCID: PMC8570423.
* Forbes AK, Hinton W, Feher MD, Elson W, Joy M, Ordóñez-Mena JM, Fan X, Cole NI, Banerjee D, Suckling RJ, de Lusignan S, Swift PA. Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study. EClinicalMedicine. 2024 Feb;68:102426. doi: 10.1016/j.eclinm.2024.102426. Epub 2024 Jan 19. PMID: 38304744; PMCID: PMC10831804.
* Siddiqui Z, Hadid S, Frishman WH. SGLT-2 Inhibitors: Focus on Dapagliflozin. Cardiol Rev. 2026 Mar-Apr 01;34(2):186-191. doi: 10.1097/CRD.0000000000000694. Epub 2024 Apr 26. PMID: 38666776.
* Butler MS, La Clair JJ. The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives. J Nat Prod. 2026 Jan 23;89(1):3-28. doi: 10.1021/acs.jnatprod.5c01368. Epub 2025 Dec 26. PMID: 41453063.
* Du P, Chen X, Xu Y, Zhou Y, Gao H. Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database. Diabetes Obes Metab. 2026 Jul;28(7):5893-5906. doi: 10.1111/dom.70790. Epub 2026 Apr 20. PMID: 42010884.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.